Berenberg analyst Harry Gillis raised the firm’s price target on Swedish Orphan Biovitrum (BIOVF) to SEK 500 from SEK 470 and keeps a Buy rating on the shares.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BIOVF:
- Swedish Orphan Biovitrum downgraded to Hold from Buy at Danske Bank
- Sobi Sets Ambitious 2030 Target to Double Revenue on Wave of New Rare-Disease Launches
- Swedish Orphan upgraded to Outperform from Underperform at BNP Paribas
- Sobi Posts Strong 2025 Growth and Expands Rare Disease Portfolio With Strategic Deals and Launches
- Swedish Orphan Biovitrum Ab (0MTD) Q4 Earnings Cheat Sheet